Anticoagulant Therapy for Cancer-Associated Thrombosis: A Cost-Effectiveness AnalysisAnn Intern Med. 2023;176:1-9. Published 27 December 2022. doi:10.7326/M22-1258In this study, the authors used data from a network meta-analysis in a Markov decision analytic model to determine the relative cost-effectiveness of enoxaparin, apixaban, rivaroxaban, and edoxaban in patients with cancer who develop venous thromboembolism (VTE). All of the direct oral anticoagulants (DOACs) were more cost-effective than enoxaparin, but the relative cost-effectiveness of the DOACs depended on the cost of the individual agents.Key points for hospitalists include:This analysis suggests that, in patients with cancer-associated ...